JACQUELINE CORRIGAN-CURAY was selected as the permanent director of the FDA Office of Medical Policy at the Center for Drug Evaluation and Research. Corrigan-Curay most recently served as a supervisory medical officer with the Immediate Office of the Director at NIH’s National Heart, Lung, and Blood Institute, where she worked on establishing a new trans-NHLBI...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
